Family Offices Fuel Biotech Boom as AI Accelerates Drug Discovery

In August, family offices completed 52 direct investments, with biotech about 20% of deals, including LifeMine Therapeutics’ $188 million Series E backed by Bezos Expeditions and Gates Frontier. Duquesne Family Office also backed Epicrispr Biotechnologies at a $90 million Series C. The moves underscore AI’s growing role in biotech and a broader VC rebound, as biotech funding reached a multi-year high in H1 2026 (about $12.6 billion in the US and Europe), even as investors skew toward later-stage programs with drugs already in testing.